TCGA-OR-A5J7-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- G2M_CHECKPOINT+0.452
- CHOLESTEROL_HOMEOSTASIS+0.422
- MYC_TARGETS_V1+0.260
- MTORC1_SIGNALING+0.256
- MYC_TARGETS_V2+0.236
- ANGIOGENESIS+0.224
- NOTCH_SIGNALING+0.224
- MITOTIC_SPINDLE+0.222
- XENOBIOTIC_METABOLISM+0.184
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.357
- INTERFERON_GAMMA_RESPONSE-0.225
- HYPOXIA-0.209
- IL2_STAT5_SIGNALING-0.191
- UV_RESPONSE_DN-0.167
- WNT_BETA_CATENIN_SIGNALING-0.164
- INFLAMMATORY_RESPONSE-0.144
- IL6_JAK_STAT3_SIGNALING-0.139
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.126
- KRAS_SIGNALING_UP-0.118
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-7579-01A-11R-2045-07 | — | cohortSQ2 | 0.825 |
| 2 | SRR10842352 | — | — | 0.737 |
| 3 | BS_P7EY9DXG | ATRT | — | 0.737 |
| 4 | s0094236 | — | — | 0.730 |
| 5 | f20785b9-991d-4b87-8ba7-ca32373f1996 | — | — | 0.729 |
| 6 | TCGA-A2-A0D4-01A-11R-A00Z-07 | — | B | 0.728 |
| 7 | TCGA-OR-A5JM-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.726 |
| 8 | MDT-AP-0843 | Med | Medulloblastoma | 0.725 |
| 9 | MNG169 | — | — | 0.720 |
| 10 | SRR8518397 | — | E | 0.719 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.452 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.422 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.256 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.236 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.224 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.224 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.222 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.184 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.175 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.173 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.162 | Idelalisib | — uncovered |
| PEROXISOME | 0.138 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.106 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.099 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.089 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.083 | Idelalisib | — uncovered |